News

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

MCK

Cardinal Health Earnings: Can Perfection Get Priced In Twice?McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Ba

Can Redwire's Phased-Array Investment Drive Defense Growth?

RDW, NOC, VSAT

RDW invests in next-generation phased-array technology to expand military communications across LEO, MEO and GEO.

Property Play: Here’s where rental demand is heading and what it means for future home sales

RSINF

As U.S. rent prices rise, more tenants are relocating to cheaper markets, according to a new report by Zillow.

Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?

BSX, ABT, GMED

BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.

Rising Risks Overshadow D-Wave Quantum Booking: Sell or Hold QBTS Now?

QBTS, IONQ, RGTI

Rising losses, weak revenue conversion and lofty valuation offset D-Wave Quantum's strong bookings and production adoption, putting the company under pressure.

Tapestry's International Growth Accelerates on China & Europe Gains

TPR, BOOT, FOSL, FIGS

TPR's overseas growth accelerates on gains in China and Europe, with customer acquisition and brand relevance supporting fiscal 2027 expansion.

AI Data Explosion: Can WDC Become a Bigger Storage Winner?

WDC, NTAP, STX

Western Digital is poised to benefit from AI-driven data growth as inference, Agentic AI and emerging workloads fuel long-term storage demand.

Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?

MRK, AZN, MRNA

MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.

3 Dividend Growth Stocks to Buy as Fed Expected to Keep Rates Higher

CAKE, ENS, VCTR

Three dividend growth stocks are here to offer income and growth potential as interest rates may stay higher for longer.